Cargando…

Bladder antimuscarinics and cognitive decline in elderly patients

INTRODUCTION: The evidence on the impact of bladder antimuscarinics initiation on cognitive function in older adults is inconsistent. METHODS: A retrospective analysis of data from the National Alzheimer's Coordinating Center (NACC) on enrollees 65 years and older evaluated the association betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moga, Daniela Claudia, Abner, Erin L., Wu, Qishan, Jicha, Gregory A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408467/ https://www.ncbi.nlm.nih.gov/pubmed/28462390 http://dx.doi.org/10.1016/j.trci.2017.01.003

Ejemplares similares

An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents
por: Moga, Daniela C., et al.
Publicado: (2017)

Use of Antimuscarinics in the Elderly
por: Patel, Bhavin, et al.
Publicado: (2009)

Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial
por: Deal, Jennifer A., et al.
Publicado: (2018)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
por: Merluzzi, Andrew P., et al.
Publicado: (2019)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
por: Kosilov, Kirill, et al.
Publicado: (2013)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

The effect of statins on rate of cognitive decline in mild cognitive impairment
por: Smith, Kyle B., et al.
Publicado: (2017)

The decline of domiciliary dentistry
por: Emanuel, Robert, et al.
Publicado: (2021)

Characteristics of subjective cognitive decline associated with amyloid positivity
por: Janssen, Olin, et al.
Publicado: (2021)

Managing patients who decline to wear a face covering
por: Hoppenbrouwers, Rupert
Publicado: (2021)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Slowing gait speed precedes cognitive decline by several years
por: Skillbäck, Tobias, et al.
Publicado: (2022)

Online study partner-reported cognitive decline in the Brain Health Registry
por: Nosheny, Rachel L., et al.
Publicado: (2018)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding
por: Yamada, Shizuo, et al.
Publicado: (2012)

Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes
por: Malpetti, Maura, et al.
Publicado: (2020)

Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women
por: Wong, Rachel H.X., et al.
Publicado: (2016)

Social interaction and cognitive decline: Results of a 7-year community intervention
por: Hikichi, Hiroyuki, et al.
Publicado: (2016)

Acceptability of patient-centered, multi-disciplinary medication therapy management recommendations: results from the INCREASE randomized study
por: Smith, Noah I., et al.
Publicado: (2023)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries
por: Aparasu, Rajender R., et al.
Publicado: (2020)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis
por: Yang, Nannan, et al.
Publicado: (2021)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Subjective cognitive decline and objective cognition among diverse U.S. Hispanics/Latinos: Results from the Study of Latinos‐Investigation of Neurocognitive Aging (SOL‐INCA)
por: Zlatar, Zvinka Z., et al.
Publicado: (2021)

Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study
por: Green, Ariel R., et al.
Publicado: (2020)

INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol
por: Moga, Daniela C., et al.
Publicado: (2019)

A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial
por: Bowman, Gene L., et al.
Publicado: (2019)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
por: Arlandis-Guzman, Salvador, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tb50vrfkhd8unnn5gr7q859g42